title: Clinical inquiries. What is the evaluation and treatment strategy for Raynaud's phenomenon?
authors.affiliation: Swedish Medical Center, Seattle, Washington, USA. htagliarino@sfm.fammed.washington.edu
authors.forename: Heather
authors.initials: H
authors.lastname: Tagliarino
authors.forename: Michael
authors.initials: M
authors.lastname: Purdon
authors.forename: Barbara
authors.initials: B
authors.lastname: Jamieson
authors.forename: Grant
authors.initials: G
authors.lastname: Hoekzema
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D019317:Evidence-Based Medicine / Q000379:methods / Q000592:standards; D006801:Humans; D009543:Nifedipine / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011224:Prazosin / Q000627:therapeutic use; D011928:Raynaud Disease / Q000175:diagnosis* / Q000628:therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D014665:Vasodilator Agents; D009543:Nifedipine; D011224:Prazosin